Having worked closely with FDA, I've been very impressed by the people there and how thoughtful they are despite the pressure they're under and the almost complete lack of good software tooling due to the sensitivity, regulatory requirements, and complexity and specialization of the data. Most of the medical officers there could easily be a very successful (and much higher paid) private physician or a pharma researcher somewhere but choose to remain at FDA.
On one point people are making specifically -- unlinking safety with efficacy is really tough -- an immunooncology product that causes serious AEs/hospitalizations in a quarter of the population and costs $250k and only extends life by 6 months may be approved because the alternative is almost certain mortality; whereas another drug may not be approved simply because it increases bleeding risk in a small percentage of people because there are good alternatives already.
On one point people are making specifically -- unlinking safety with efficacy is really tough -- an immunooncology product that causes serious AEs/hospitalizations in a quarter of the population and costs $250k and only extends life by 6 months may be approved because the alternative is almost certain mortality; whereas another drug may not be approved simply because it increases bleeding risk in a small percentage of people because there are good alternatives already.